In contrast, mice transplanted with RUNX1-ETO9a-transduced Cas9 cells with intact Trp53 showed considerable variation in disease onset time, with only 5 out of 7 mice developed AML (Fig. 1B). This evidence concerns the gene TP53 and acute myeloid leukemia.